Our Impact

Our commitment to patients and their health is steadfast. We recognise this tremendous responsibility and also see it as an opportunity for us to improve lives and to make a lasting social impact

Contributing to Healthy Communities

We contribute to healthy communities by increasing access to affordable treatments, driving science and innovation, engaging patients as well as their caregivers and healthcare professionals and advancing global health priorities

Learn more Contributing to Healthy Communities

Leading a Responsible Business

We lead a responsible business by promoting compliance, ethics and transparency, protecting the environment, improving sustainability across our supply chain, ensuring patient safety and engaging and supporting our people

Learn more Leading a Responsible Business

Our commitment

We are dedicated to promoting health and increasing access to treatment for patients

Learn more

Patient Advocacy

We believe in the value of relationships to develop a deeper understanding of patients' needs

Learn more


We maintain high standards in how we promote our medicines and we're transparent in how we work

Read more

Environmental, Social & Governance Report (ESG)

We align our corporate resources and expertise with relevant areas of global health and social need

Read more

UK & Ireland Environmental, Social & Governance Report

As one of the largest suppliers of medicines to both the UK & Ireland, we take our responsibility to patients, our customers and our communities incredibly seriously.

Read more UK & Ireland Environmental, Social & Governance Report

Teva’s Global Economic Impact Report

Our work impacts economies and healthcare systems around the world

Learn more Teva’s Global Economic Impact Report

A global health challenge

With the extensive range of medicines we provide to healthcare providers all around the world, we are uniquely positioned to improve understanding and treatment of patients with multiple chronic conditions

Learn more A global health challenge
Date of preparation: November 2021
Reference: COB-IE-NP-00074